155 related articles for article (PubMed ID: 2105840)
1. Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity.
Chapman PB; Lonberg M; Houghton AN
Cancer Res; 1990 Mar; 50(5):1503-9. PubMed ID: 2105840
[TBL] [Abstract][Full Text] [Related]
2. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma.
Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ
Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480
[TBL] [Abstract][Full Text] [Related]
3. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
Helfand SC; Dickerson EB; Munson KL; Padilla ML
Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
[TBL] [Abstract][Full Text] [Related]
4. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells.
Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ
Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201
[TBL] [Abstract][Full Text] [Related]
5. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
[TBL] [Abstract][Full Text] [Related]
6. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside.
Chapman PB; Yuasa H; Houghton AN
J Immunol; 1990 Aug; 145(3):891-8. PubMed ID: 1695649
[TBL] [Abstract][Full Text] [Related]
7. Anti-GD3 monoclonal antibody analysis of childhood T-cell acute lymphoblastic leukemia: detection of a target antigen for antibody-mediated cytolysis.
Reaman GH; Taylor BJ; Merritt WD
Cancer Res; 1990 Jan; 50(1):202-5. PubMed ID: 2403416
[TBL] [Abstract][Full Text] [Related]
8. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
[TBL] [Abstract][Full Text] [Related]
9. Production and molecular characterization of clinical phase i anti-melanoma mouse IgG3 monoclonal antibody R24.
Kemminer SE; Conradt HS; Nimtz M; Sagi D; Peter-Katalinić J; Diekmann O; Drmić I; Müthing J
Biotechnol Prog; 2001; 17(5):809-21. PubMed ID: 11587568
[TBL] [Abstract][Full Text] [Related]
10. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody.
Chapman PB; Gillies SD; Houghton AN; Reilly RM
Cancer Immunol Immunother; 1994 Sep; 39(3):198-204. PubMed ID: 7522964
[TBL] [Abstract][Full Text] [Related]
11. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity.
Thurin J; Thurin M; Kimoto Y; Herlyn M; Lubeck MD; Elder DE; Smereczynska M; Karlsson KA; Clark WM; Steplewski Z
Cancer Res; 1987 Mar; 47(5):1229-33. PubMed ID: 3815333
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.
Wolff EA; Schreiber GJ; Cosand WL; Raff HV
Cancer Res; 1993 Jun; 53(11):2560-5. PubMed ID: 8495420
[TBL] [Abstract][Full Text] [Related]
14. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
15. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
[TBL] [Abstract][Full Text] [Related]
16. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
17. Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen.
Yan X; Evans SV; Kaminki MJ; Gillies SD; Reisfeld RA; Houghton AN; Chapman PB
J Immunol; 1996 Aug; 157(4):1582-8. PubMed ID: 8759742
[TBL] [Abstract][Full Text] [Related]
18. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
